Clark A - Search Results

1

The projected cost-effectiveness and budget impact of HPV vaccine introduction in Ghana.

Vodicka E, Nonvignon J, Antwi-Agyei KO, Bawa J, Clark A, Pecenka C, LaMontagne DS. Vodicka E, et al. Among authors: clark a. Vaccine. 2022 Mar 31;40 Suppl 1:A85-A93. doi: 10.1016/j.vaccine.2021.07.027. Epub 2021 Jul 21. Vaccine. 2022. PMID: 34303563 Free article.

2

Cost-effectiveness of rotavirus vaccination in peru.

Clark AD, Walker DG, Mosqueira NR, Penny ME, Lanata CF, Fox-Rushby J, Sanderson CF. Clark AD, et al. J Infect Dis. 2009 Nov 1;200 Suppl 1:S114-24. doi: 10.1086/605043. J Infect Dis. 2009. PMID: 19817591

3

Cost-effectiveness of Haemophilus influenzae type b conjugate vaccine in low- and middle-income countries: regional analysis and assessment of major determinants.

Griffiths UK, Clark A, Hajjeh R. Griffiths UK, et al. Among authors: clark a. J Pediatr. 2013 Jul;163(1 Suppl):S50-S59.e9. doi: 10.1016/j.jpeds.2013.03.031. J Pediatr. 2013. PMID: 23773595 Free PMC article.

4

Impact and cost-effectiveness of Haemophilus influenzae type b conjugate vaccination in India.

Clark AD, Griffiths UK, Abbas SS, Rao KD, Privor-Dumm L, Hajjeh R, Johnson H, Sanderson C, Santosham M. Clark AD, et al. J Pediatr. 2013 Jul;163(1 Suppl):S60-72. doi: 10.1016/j.jpeds.2013.03.032. J Pediatr. 2013. PMID: 23773596 Free PMC article.

5

TRIVAC decision-support model for evaluating the cost-effectiveness of Haemophilus influenzae type b, pneumococcal and rotavirus vaccination.

Clark A, Jauregui B, Griffiths U, Janusz CB, Bolaños-Sierra B, Hajjeh R, Andrus JK, Sanderson C. Clark A, et al. Vaccine. 2013 Jul 2;31 Suppl 3:C19-29. doi: 10.1016/j.vaccine.2013.05.045. Vaccine. 2013. PMID: 23777686

6

Evaluating the potential risks and benefits of infant rotavirus vaccination in England.

Clark A, Jit M, Andrews N, Atchison C, Edmunds WJ, Sanderson C. Clark A, et al. Vaccine. 2014 Jun 17;32(29):3604-10. doi: 10.1016/j.vaccine.2014.04.082. Epub 2014 May 9. Vaccine. 2014. PMID: 24814524

7

Cost-effectiveness of rotavirus vaccination in Kenya and Uganda.

Sigei C, Odaga J, Mvundura M, Madrid Y, Clark AD; Kenya ProVac Technical Working Group; Uganda ProVac Technical Working Group. Sigei C, et al. Vaccine. 2015 May 7;33 Suppl 1:A109-18. doi: 10.1016/j.vaccine.2014.12.079. Vaccine. 2015. PMID: 25919149

8

Estimated impact and cost-effectiveness of rotavirus vaccination in Senegal: A country-led analysis.

Diop A, Atherly D, Faye A, Lamine Sall F, Clark AD, Nadiel L, Yade B, Ndiaye M, Fafa Cissé M, Ba M. Diop A, et al. Among authors: clark ad. Vaccine. 2015 May 7;33 Suppl 1:A119-25. doi: 10.1016/j.vaccine.2014.12.065. Vaccine. 2015. PMID: 25919151

9

Cost-effectiveness analysis of introducing universal human papillomavirus vaccination of girls aged 11 years into the National Immunization Program in Brazil.

Novaes HM, de Soárez PC, Silva GA, Ayres A, Itria A, Rama CH, Sartori AM, Clark AD, Resch S. Novaes HM, et al. Among authors: clark ad. Vaccine. 2015 May 7;33 Suppl 1:A135-42. doi: 10.1016/j.vaccine.2014.12.031. Vaccine. 2015. PMID: 25919154

10

Cost-effectiveness analysis of pneumococcal conjugate vaccine introduction in Paraguay.

Kieninger MP, Caballero EG, Sosa AA, Amarilla CT, Jáuregui B, Janusz CB, Clark AD, Castellanos RM. Kieninger MP, et al. Vaccine. 2015 May 7;33 Suppl 1:A143-53. doi: 10.1016/j.vaccine.2014.12.078. Vaccine. 2015. PMID: 25919155

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

8,238 results

Search Page

Filters